A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is a study of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects
birth to ≤ 48 months of age who go to the Emergency Department (ED) or their physician's
office with an acute bronchospasm. Subjects presenting to the ED or physician's office with
an acute bronchospasm must have a history of reactive airways disease, based on subjects'
parent/guardian report.